Merck is the world's top pharmaceutical and research company. Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories found in 140 countries.
The company's top products include: Zetia, which helps reduce cholesterol; Januvia, which treats Type 2 diabetes; Remicate, a treatment for inflammatory diseases; Singulair, which treats asthma and allergies; Propecia, which helps treat male hair loss.
Merck is known as MSD outside of the U.S. and Canada.
The process of drug discovery and development is long and challenging. It begins by first exploring the roots of a disease or condition. If a compound proves promising, it then continues through years of testing and has to obtain regulatory approval before it reaches the market. A very small fraction of the compounds that commence evaluation will ultimately survive the tough process of research, development and testing to finally become medicines.
In 2015, Merck reported worldwide sales of $39.5 billion, down 6% due to negative currency impact and acquisitions, with net income of $4.4 billion. The company spent $6.7 billion on research and development last year, a slight increase from the previous year.
Januvia/Janumet was the top selling medication at Merck generating $6.0 billion in sales last year followed by Zetia/Vytorin with $3.7 billion in sales.
Full-year 2015 worldwide sales for SINGULAIR were $931 million, a 15% decrease compared to the prior year. The patent for SINGULAIR expired in the United States in August 2012 and in major European markets in February 2013.
"The past year was one of considerable progress and execution for Merck," said Kenneth Frazier, chairman and chief executive officer, Merck. "I'm excited by the near-term opportunities, as we continue launching important new products like ZEPATIER and KEYTRUDA while augmenting and advancing our pipeline."
Merck moved its headquarters from Whitehouse Station, NJ to facilities in Kenilworth, NJ in 2015.
Established in 1891 by George Merck, the company started off as a fine chemicals supplier. Merck & Co., Inc began its pharmaceutical research in the early 1930's. The merger with Sharp & Dohme to create Merck Sharp & Dohme (MSD) in 1953 established a solid foundation for a fully integrated, multi-national producer and distributor of pharmaceutical products.
Merck & Co., Inc acquired Medco Containment Services, Inc. in 1993, the leading pharmacy benefits management company in the United States. Medco was spun off as an independent company in 2003.
The company acquired Schering Plough in Dec. 2009 for $41 billion.
Merck acquired Inspire Pharmaceuticals in 2011.
- Competitive Base Salary
A Flexible Benefits package including:
Updated February 3, 2016